A phase II study of doxifluridine in elderly patients with advanced gastric cancer: The Japan Clinical Oncology Group study (JCOG 9410)

Japanese Journal of Clinical Oncology

Volumn 32, Issue 3, 2002, Pages 90-94

  Ikeda, Nobumasa ^a   Shimada, Yasuhiro ^b   Ohtsu, Atsushi ^c   Boku, Narikazu ^c   Tsuji, Yasushi ^d   Saito, Hiroshi ^e   Koizumi, Wasaburo ^f   Iwase, Hiroaki ^g   Yoshida, Shigeaki ^c   Fukuda, Haruhiko ^h  

^a Mitoyo General Hospital   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d Tonan Hospital   (Japan)

^e YAMAGATA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f KITASATO UNIVERSITY HOSPITAL   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Doxifluridine; Elderly patients; Gastric cancer

Indexed keywords

DOXIFLURIDINE; ANTINEOPLASTIC ANTIMETABOLITE; FLOXURIDINE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; JAPAN; MALE; NAUSEA AND VOMITING; STOMACH CANCER; SURVIVAL; THROMBOCYTOPENIA; DRUG ADMINISTRATION; MORTALITY; PHASE 2 CLINICAL TRIAL; REGISTER; STOMACH TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; HUMANS; MALE; REGISTRIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0036516622     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyf022     Document Type: Article

References (19)

1. Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigeues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
2. Glimelius B, Hotfmann K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90.
3. Pyrhonen S, Kuitumen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;1:587-91.
4. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980;71:112-23.
5. Kono A, Hara Y, Sugita S, Karube Y, Matsushima Y, Ishituka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983;31:175-8.
6. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, et al. Phase II study of 5′-deoxy-5-fluorouridine (5′DFUR) on patients with malignant cancer - multi-institutional cooperative study. Gan To Kagaku Ryoho 1985;12:2044-51 (in Japanese).
7. Shimoyama M, Fukuda H, Saijo N, Yamaguchi N and Members of the Committees for the Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol 1998;28:158-62.
8. Niitani H, Kurihara M, Hasegawa K, Hatta Y, Suwa T, Tsuboi H, et al. Randomized comparison of continuous and oral administration of 5′-deoxy-5-fluorouridine in the treatment of advanced gastric cancer: a phase II multi-institutional cooperative study group. Gan To Kagaku Ryoho 1987;14:3345-50 (in Japanese).
9. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, et al. A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993;72:658-62.
10. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma, 1st Engl ed, Nishi M, Omori Y, Miwa Y, editors. Part IV. Response Assessment of Chemotherapy for Gastric Carcinoma. Kanehara Syuppan: Tokyo 1995;89-100.
11. Tobinai K, Kohno A, Shimada Y, Tamura T, Saijo N, Shimoyama M, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
12. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987;71:1079-85.
13. Sasaki T, Maeda Y, Sato A, Kurihara M. Cancer chemotherapy in patients of advanced age (over 75). Gan To Kagaku Ryoho 1998;25:973-9 (in Japanese).
14. Taguchi T. 5′-DFUR (doxifluridine). Gan To Kagaku Ryoho 1987;14:2235-43 (in Japanese).
15. Urushizaki I. Chemotherapy for older cancer patients. Gan To Kagaku Ryoho 1993;20:850-7 (in Japanese).
16. Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, et al. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 1993;84:341-7.
17. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989;16:66-75.
18. Kubota K, Furuse K, Kawahara M, Kodama N, Ogawara M, Takada M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol 1997;40:469-74.
19. Falcone A, Pfanner E, Ricci S, Bertuccelli M, Cianci C, Carrai M, et al. Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. Ann Oncol 1994;5:760-2.